Lymphoma Drugs Market Research Reports

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034 - Product Thumbnail Image

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034

  • Drug Pipelines
  • 162 Pages
From
NHL: Follicular Lymphoma Forecast and Market Analysis to 2025 - Product Thumbnail Image

NHL: Follicular Lymphoma Forecast and Market Analysis to 2025

  • Drug Pipelines
  • 229 Pages
From
Market Spotlight: Waldenström Macroglobulinemia (WM) - Product Thumbnail Image

Market Spotlight: Waldenström Macroglobulinemia (WM)

  • Report
  • 32 Pages
From
NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034 - Product Thumbnail Image

NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034

  • Report
  • 196 Pages
From
Global Non-Hodgkin Lymphoma Partnering 2012 to 2018 - Product Thumbnail Image

Global Non-Hodgkin Lymphoma Partnering 2012 to 2018

  • Report
  • 150 Pages
From
Global Lymphoma Partnering 2012 to 2018 - Product Thumbnail Image

Global Lymphoma Partnering 2012 to 2018

  • Report
  • 150 Pages
From
Non-Hodgkin Lymphoma Forecast in 18 Major Markets 2017-2027 - Product Thumbnail Image

Non-Hodgkin Lymphoma Forecast in 18 Major Markets 2017-2027

  • Report
  • 92 Pages
From
Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026 - Product Thumbnail Image

Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

  • Report
  • 60 Pages
From
Non-Hodgkin Lymphoma - Heat Map and Analysis - Product Thumbnail Image

Non-Hodgkin Lymphoma - Heat Map and Analysis

  • Drug Pipelines
  • 15 Pages
From
CAS 936563-96-1 PCI-32765 Chemical World Report - Product Thumbnail Image

CAS 936563-96-1 PCI-32765 Chemical World Report

  • Report
  • 2069 Pages
CAS 23214-92-8 Adriamycin Chemical World Report - Product Thumbnail Image

CAS 23214-92-8 Adriamycin Chemical World Report

  • Report
  • 2153 Pages
CAS 4342-03-4 Dacarbazine Chemical World Report - Product Thumbnail Image

CAS 4342-03-4 Dacarbazine Chemical World Report

  • Report
  • 2141 Pages
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Pipeline Review, H1 2018 - Product Thumbnail Image

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Pipeline Review, H1 2018

  • Report
  • 32 Pages
From
Lymphoma Treatment Drugs Companies in China - Product Thumbnail Image

Lymphoma Treatment Drugs Companies in China

  • Report
  • 71 Pages
From
Non-Hodgkin Lymphoma - Pipeline Review, H1 2018 - Product Thumbnail Image

Non-Hodgkin Lymphoma - Pipeline Review, H1 2018

  • Report
  • 2186 Pages
From
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H1 2018 - Product Thumbnail Image

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H1 2018

  • Report
  • 81 Pages
From
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H1 2018 - Product Thumbnail Image

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H1 2018

  • Report
  • 71 Pages
From
Lymphoma Treatment Drugs Industry Forecasts - China Focus - Product Thumbnail Image

Lymphoma Treatment Drugs Industry Forecasts - China Focus

  • Report
  • 84 Pages
From
Lymphoma Treatment Drugs Markets in China - Product Thumbnail Image

Lymphoma Treatment Drugs Markets in China

  • Report
  • 206 Pages
From
Cutaneous T-Cell Lymphoma(CTCL) - Market Insight, Epidemiology and Market Forecast - 2027 - Product Thumbnail Image

Cutaneous T-Cell Lymphoma(CTCL) - Market Insight, Epidemiology and Market Forecast - 2027

  • Drug Pipelines
  • 154 Pages
From
Loading Indicator

Lymphoma encompasses a variety of blood cancers of the lymphatic system. Non-Hodgkin’s Lymphoma (NHL) for example, is diagnosed in over 100,000 every year in the US and EU combined. An array of expert reports in our Lymphoma Section enable you to investigate drug development strategies and market trends for NHL, Hodgkin’s Lymphoma, Skin Lymphoma, T-Cell Lymphoma, Indolent Lymphoma and other variants. Investigate key issues such as licensing, R&D, industry alliances, generic drugs (rituximab, bortezomib, doxorubicin, bleomycin, vinblastine, etc.) and the activities of major pharmaceutical players such as Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Show Less Read more

adroll